« Previous Next » Journal of Pain and Symptom Management
Volume 27, Issue 3 , Pages 194-195 , March 2004

Use of thioridazine in palliative care patients with troublesome sweating

References

Mortimer PS. Management of skin problems. Sweating. In: Doyle D, Hanks GWC, MacDonald N editor. Oxford textbook of palliative medicine. 2nd ed.. Oxford: Oxford University Press; 1998;p. 636–642
Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage. 1994;6:372–382
Quigley SC, Baines M. Descriptive epidemiology of sweating in a hospice population. J Palliative Care. 1997;13:22–26
Tsavaris N, Zinelis A, Karabelis , et al. A randomized trial of the effect of three non-steroidal anti-inflammatory agents in ameliorating cancer-induced fever. J Intern Med. 1990;228:451–455
- MEDLINE
- CrossRef
Zyclicz Z, Krajnik M. Flushing and sweating in an advanced breast cancer patient relieved by olanzapine. J Pain Symptom Manage. 2003;25:494–495
Regnard C. Use of low dose thioridazine to control sweating in advanced cancer. Pall Medicine. 1996;10:78–79
Cowap J, Hardy J. Thioridazine in the management of cancer related sweating. J Pain Symptom Manage. 1998;15:266
- Full-Text PDF (74 KB)
- CrossRef
Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol. 1995;33:199–204
- MEDLINE
Antipsychotic drugs. Section 4.2.1. British National Formulary 46; British Medical Association and the Royal Pharmaceutical Society of Great Britain. London, 2003.
Reilly JG, Aysis SA, Ferrier IN, et al. QTc-interval abnormalities and antipsychotic drug therapy in psychiatric patients. Lancet. 2000;355:1048–1052
Walker G, Wilcock A, Carey AM, et al. Prolongation of QT interval in palliative care patients. J Pain Symptom Manage. 2003;26:855–859